Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA21258
Max Phase: Preclinical
Molecular Formula: C18H23N7O2S
Molecular Weight: 401.50
Molecule Type: Small molecule
Associated Items:
ID: ALA21258
Max Phase: Preclinical
Molecular Formula: C18H23N7O2S
Molecular Weight: 401.50
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC1(C)N=C(N)N=C(N)N1c1cccc(CNc2ccc(S(N)(=O)=O)cc2)c1
Standard InChI: InChI=1S/C18H23N7O2S/c1-18(2)24-16(19)23-17(20)25(18)14-5-3-4-12(10-14)11-22-13-6-8-15(9-7-13)28(21,26)27/h3-10,22H,11H2,1-2H3,(H2,21,26,27)(H4,19,20,23,24)
Standard InChI Key: JFDMBYLFKZHPHM-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 401.50 | Molecular Weight (Monoisotopic): 401.1634 | AlogP: 1.13 | #Rotatable Bonds: 5 |
Polar Surface Area: 152.19 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 4 |
#RO5 Violations: 0 | HBA (Lipinski): 9 | HBD (Lipinski): 7 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 10.96 | CX Basic pKa: 8.21 | CX LogP: 0.90 | CX LogD: 0.04 |
Aromatic Rings: 2 | Heavy Atoms: 28 | QED Weighted: 0.59 | Np Likeness Score: -1.10 |
1. Booth RG, Selassie CD, Hansch C, Santi DV.. (1987) Quantitative structure-activity relationship of triazine-antifolate inhibition of Leishmania dihydrofolate reductase and cell growth., 30 (7): [PMID:3599028] [10.1021/jm00390a017] |
2. Coats EA, Genther CS, Dietrich SW, Guo ZR, Hansch C.. (1981) Comparison of the inhibition of methotrexate-sensitive and -resistant Lactobacillus casei cell cultures with purified Lactobacillus casei dihydrofolate reductase by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(3-substituted-phenyl)-s-triazines. Use of quantitative structure-activity relationships in making inferences about the mechanism of resistance and the structure of the enzyme is situ compared with the enzyme in vitro., 24 (12): [PMID:6796688] [10.1021/jm00144a010] |
3. Hansch C, Hathaway BA, Guo ZR, Selassie CD, Dietrich SW, Blaney JM, Langridge R, Volz KW, Kaufman BT.. (1984) Crystallography, quantitative structure-activity relationships, and molecular graphics in a comparative analysis of the inhibition of dihydrofolate reductase from chicken liver and Lactobacillus casei by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(substituted-phenyl)-s-triazine s., 27 (2): [PMID:6420569] [10.1021/jm00368a006] |
4. Khwaja TA, Pentecost S, Selassie CD, Guo Z, Hansch C.. (1982) Comparison of quantitative structure-activity relationships of the inhibition of leukemia cells in culture with the inhibition of dihydrofolate reductase from leukemia cells and other cell types., 25 (2): [PMID:7057420] [10.1021/jm00344a012] |
5. Selassie CD, Guo Z, Hansch C, Khwaja TA, Pentecost S.. (1982) A comparison of the inhibition of growth of methotrexate-resistant and -sensitive leukemia cells in culture by triazines. Evidence for a new mechanism of cell resistance to methotrexate., 25 (2): [PMID:7057421] [10.1021/jm00344a013] |
6. Selassie CD, Hansch C, Khwaja TA, Dias CB, Pentecost S.. (1984) Comparative structure-activity relationships of antifolate triazines inhibiting murine tumor cells sensitive and resistant to methotrexate., 27 (3): [PMID:6699880] [10.1021/jm00369a019] |
7. Marlowe CK, Selassie CD, Santi DV.. (1995) Quantitative structure-activity relationships of the inhibition of Pneumocystis carinii dihydrofolate reductase by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(X-phenyl)-s-triazines., 38 (6): [PMID:7699713] [10.1021/jm00006a016] |
Source(1):